Literature DB >> 28414251

Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia.

Sun Gu Park1, Jeong Kyun Yeo2, Dae Yeon Cho3, Min Gu Park2.   

Abstract

OBJECTIVE: The objective of this study is to investigate the impact of metabolic status on associations of serum vitamin D with hypogonadism and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: A total of 612 men underwent physical examination, biochemical/hormonal blood testing, and transrectal prostate ultrasound. Moreover, the subjects filled out standard questionnaires for identification and grading of LUTS and hypogonadism symptoms. Parameters were statistically compared with independent t-tests and correlation analyses.
RESULTS: Vitamin D levels positively correlated with total testosterone (TT) but not with prostate volume or International Prostate Symptom Score (IPSS). Patients with metabolic syndrome had significantly lower vitamin D levels, which were not correlated with TT, prostate volume, or IPSS. However, vitamin D was positively correlated with TT, and negatively correlated with prostate volume and quality-of-life IPSS in subjects without metabolic syndrome.
CONCLUSION: The clinical usefulness of vitamin D for treatment of hypogonadism or LUTS/BPH varies according to metabolic status.

Entities:  

Keywords:  Serum vitamin D; benign prostate hyperplasia; hypogonadism; lower urinary tract symptoms; metabolic syndrome; testosterone

Mesh:

Substances:

Year:  2017        PMID: 28414251     DOI: 10.1080/13685538.2017.1311857

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  5 in total

1.  Relationship of Vitamin D status with testosterone levels: a systematic review and meta-analysis.

Authors:  S D'Andrea; A Martorella; F Coccia; C Castellini; E Minaldi; M Totaro; A Parisi; F Francavilla; S Francavilla; A Barbonetti
Journal:  Endocrine       Date:  2020-09-03       Impact factor: 3.633

2.  Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.

Authors:  Asma Omran; Bianca M Leca; Eduard Oštarijaš; Natasha Graham; Ana Sofia Da Silva; Zoulikha M Zaïr; Alexander D Miras; Carel W le Roux; Royce P Vincent; Linda Cardozo; Georgios K Dimitriadis
Journal:  Ther Adv Endocrinol Metab       Date:  2021-12-08       Impact factor: 3.565

3.  Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence.

Authors:  Yanbo Chen; Hui Xu; Chong Liu; Meng Gu; Qi Chen; Ming Zhan; Zhong Wang
Journal:  Dis Markers       Date:  2021-10-11       Impact factor: 3.434

4.  Relationship between outpatient duration of young outpatient physicians and lower urinary tract symptoms and sexual dysfunction.

Authors:  Qing-Tian Song; Xiang Chen; Yu-Chen Gong; Sheng Liu
Journal:  Transl Androl Urol       Date:  2022-09

5.  An investigation on the relevance of prolactin, insulin-like growth factor-1 and 25-hydroxyvitamin D3 (25-OHD3 ) in canine benign prostatic hyperplasia in a predisposed breed model.

Authors:  Franziska Werhahn Beining; Marion Schmicke; Mirja Wilkens; Karola Wolf; Karl Rohn; Anne-Rose Günzel-Apel
Journal:  Vet Med Sci       Date:  2021-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.